Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis

医学 黑色素瘤 癌症研究 肿瘤科 脑转移 内科学 转移 癌症
作者
Ester Bonfill‐Teixidor,Raffaella Iurlaro,Cornelia Handl,Jürgen Wichmann,Alexandra Arias,Isabel Cuartas,Jasmin Emmenegger,Andrea Romagnani,Luca Mangano,Thomas Lorber,Marco Berrera,Christina Godfried Sie,Fabian Köchl,Jan Eckmann,Romi Feddersen,Martin Kornacker,Gabriel Schnetzler,Marta Cicuéndez,Esteban Cordero,Thomaz Eduardo Topczewski
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (14): 2552-2564 被引量:11
标识
DOI:10.1158/0008-5472.can-21-4152
摘要

The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K-mutated melanoma is limited and transient. Resistance largely occurs through the restoration of MAPK signaling via paradoxical BRAF activation, highlighting the need for more effective therapeutic options. Aiming to address this clinical challenge, we characterized the activity of a potent, brain-penetrant paradox breaker BRAFi (compound 1a, C1a) as first-line therapy and following progression upon treatment with approved BRAFi and BRAFi/MEKi therapies. C1a activity was evaluated in vitro and in vivo in melanoma cell lines and patient-derived models of BRAF V600E-mutant melanoma brain metastases following relapse after treatment with BRAFi/MEKi. C1a showed superior efficacy compared with approved BRAFi in both subcutaneous and brain metastatic models. Importantly, C1a manifested potent and prolonged antitumor activity even in models that progressed on BRAFi/MEKi treatment. Analysis of mechanisms of resistance to C1a revealed MAPK reactivation under drug treatment as the predominant resistance-driving event in both subcutaneous and intracranial tumors. Specifically, BRAF kinase domain duplication was identified as a frequently occurring driver of resistance to C1a. Combination therapies of C1a and anti-PD-1 antibody proved to significantly reduce disease recurrence. Collectively, these preclinical studies validate the outstanding antitumor activity of C1a in brain metastasis, support clinical investigation of this agent in patients pretreated with BRAFi/MEKi, unveil genetic drivers of tumor escape from C1a, and identify a combinatorial treatment that achieves long-lasting responses. SIGNIFICANCE: A brain-penetrant BRAF inhibitor demonstrates potent activity in brain metastatic melanoma, even upon relapse following standard BRAF inhibitor therapy, supporting further investigation into its clinical utility.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
MM1_8完成签到,获得积分10
1秒前
得得祎祎发布了新的文献求助20
1秒前
1秒前
十一发布了新的文献求助10
1秒前
1秒前
桐桐的应助被稳重的秋天采纳,获得10
2秒前
2秒前
2秒前
Limerence完成签到,获得积分10
3秒前
ZhaoMinHui完成签到 ,获得积分10
3秒前
3秒前
3秒前
洋洋得意完成签到,获得积分10
4秒前
4秒前
4秒前
怡然的幻灵完成签到,获得积分10
4秒前
淡淡的代云完成签到,获得积分20
4秒前
Debbie的应助被务实的手套采纳,获得10
5秒前
谦让疾发布了新的文献求助10
6秒前
雨姐科研发布了新的文献求助10
7秒前
7秒前
PP的应助被Icey采纳,获得30
7秒前
7秒前
天天快乐的应助被SiqiZhang采纳,获得10
7秒前
呜呼完成签到,获得积分10
7秒前
cbx发布了新的文献求助10
8秒前
bkagyin的应助被日薪月亿采纳,获得10
8秒前
8秒前
8秒前
bu发布了新的文献求助10
8秒前
an发布了新的文献求助10
8秒前
爆米花的应助被liwen采纳,获得10
9秒前
Eon完成签到,获得积分10
9秒前
2021014035发布了新的文献求助10
9秒前
二十八画生完成签到 ,获得积分10
9秒前
10秒前
温暖的鹏飞完成签到,获得积分10
10秒前
WJ发布了新的文献求助10
10秒前
0227Y完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160526
求助须知:如何正确求助?哪些是违规求助? 9555475
关于积分的说明 21728510
捐赠科研通 7750342
什么是DOI,文献DOI怎么找? 3427395
关于科研通互助平台的介绍 2552448
邀请新用户注册赠送积分活动 2471795